Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Total Debt (2016 - 2025)

Angiodynamics (ANGO) has disclosed Total Debt for 15 consecutive years, with $5.0 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Total Debt fell 47.37% year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Feb 2025, down 47.37%, and an annual FY2024 reading of $4.7 million, down 92.68% over the prior year.
  • Total Debt was $5.0 million for Q1 2025 at Angiodynamics, up from $5.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $64.6 million in Q2 2023 and bottomed at $4.7 million in Q2 2024.
  • Average Total Debt over 5 years is $26.1 million, with a median of $25.0 million recorded in 2021.
  • The sharpest move saw Total Debt surged 138.74% in 2023, then crashed 92.68% in 2024.
  • Year by year, Total Debt stood at $25.0 million in 2021, then soared by 138.22% to $59.6 million in 2022, then plummeted by 84.24% to $9.4 million in 2023, then crashed by 47.16% to $5.0 million in 2024, then rose by 0.81% to $5.0 million in 2025.
  • Business Quant data shows Total Debt for ANGO at $5.0 million in Q1 2025, $5.0 million in Q4 2024, and $4.8 million in Q3 2024.